Liberty Analytics Co. Initiates Independent Research Coverage on CombinatoRx, Inc.
26 Março 2010 - 10:15AM
Liberty Analytics Co., a leading provider of large, small- and
micro-cap independent investment research, today initiated coverage
on CombinatoRx, Inc. (Nasdaq:CRXX). Liberty Analytics is currently
offering a complimentary trial subscription. To view our research,
go to: www.libertyanalyticsco.com.
About LAC:
Liberty Analytics Co. is a leading provider of independent
investment research in North America. Our services include research
analysis on the large, small- and micro-cap markets, real-time news
and financial data, market commentary and the LAC newsletter.
Liberty Analytics' staff of large and small-cap investment
professionals is dedicated to providing the market's investment
community with the tools and avenues necessary to make the
important investment decisions. To view our research reports on a
complimentary trial basis and take advantage of our other services,
go to www.libertyanalyticsco.com and click on the complimentary
trial subscription button on our home page, or go directly to our
registration page at www.libertyanalyticsco.com/signup.php.
About CombinatoRx, Inc. (Nasdaq:CRXX)
CombinatoRx, Inc. (Nasdaq:CRXX) is a biopharmaceutical company
focused on developing synergistic combination pharmaceuticals.
LAC Disclosure:
Libertyanalyticsco.com is not a registered investment advisor
and nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. Liberty Analytics has
not been compensated by any of the above-mentioned companies.
Please read our report and visit our Web site,
www.libertyanalyticsco.com, for complete risks and disclosures.
CONTACT: Liberty Analytics
Kevin Mix
480-626-1850
info@libertyanalyticsco.com
Combinatorx (NASDAQ:CRXX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Combinatorx (NASDAQ:CRXX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Combinatorx, Incorporated - Common (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de